Almirall stock heads into the open after a 2.25% drop

At the close on September 9, 2026, Almirall stock finished at EUR 78.20 on its Spanish home market, down 2.25% with about 45,700 shares traded. The move came as investors continued to weigh recent half-year 2026 figures and sector sentiment.

Almirall stock closed at EUR 78.20 on its Spanish home market on September 9, 2026, down 2.25% from the previous session, based on exchange data. That decline left the shares lagging broader European health-care benchmarks on the day.

September 9, 2026 in numbers

Almirall S.A. (ISIN ES0157097017) ended the session on September 9, 2026 at EUR 78.20, marking a 2.25% loss compared with the prior close, on a trading volume of 45,743 shares according to market data cited in a recent wrap at Ad-hoc-news. The same report noted that investors continued to react to Almirall’s half-year 2026 figures and guidance commentary from earlier in the week, framing the latest move as part of that adjustment phase, and highlighted that a group of eight analysts tracked by MarketScreener carried an average target of EUR 102.94 for the shares, underscoring the gap between the current price and prevailing expectations.

The closing level of EUR 78.20 on September 9, 2026 left Almirall trading significantly below that cited average target of EUR 102.94, a difference of roughly EUR 24.74 per share, which quantifies the room implied by those analyst projections. Within the same session, the broader European equity indices were described as mixed in sector-focused commentary, suggesting that Almirall’s 2.25% decline represented a stock-specific move rather than a uniform sector slide, even as dermatology and immunology peers faced their own shifts in sentiment detailed in industry coverage such as the alopecia areata market analysis from OpenPR, which cited Almirall as holding an estimated 3.5% share of that segment. Taken together, the latest close, the trading volume, and the distance to the analyst average target offer a concise numerical profile of how the stock entered today’s pre-market phase.

Today’s key drivers

Today, Almirall stock heads into the open without a fresh company-specific announcement in the very early hours referenced in the available coverage, meaning that previously released half-year 2026 information and ongoing analyst views remain the main known company-level inputs shaping sentiment at the start of the session as described by Ad-hoc-news. In the broader context, industry commentary such as the alopecia areata market outlook from OpenPR continues to underline structural growth expectations in key dermatology niches where Almirall is active, which can frame medium-term investor discussions even if it does not represent a discrete trading catalyst for today. With no specific dated corporate event or earnings release identified for September 11, 2026 in the latest week’s public calendars, the stock’s path into today’s session will be shaped by how investors balance the recent price weakness against those longer-term sector growth narratives and the still-elevated analyst price targets referenced in recent reports.